Response to hormonal treatment of young females with primary or very premature ovarian failure

References

• Ballabio A, Andria G. Deletions and translocations involving the distal short arm of the human X chromosome: review and hypotheses. Hum Mol Genet 1992;1:221–227.
   PubMedGoogle Scholar
• Hall JG, Gilchrist DM. Turner syndrome and its variants. Pediatr Clin North Am 1990;37:1421–1440.
   PubMed Web of Science ®Google Scholar
• Mathur A, Stekol L, Schatz D, MacLaren NK, Scott ML, Lippe B. The parental origin of the single X chromosome in Turner syndrome: lack of correlation with parental age or clinical phenotype. Am J Hum Genet 1991;48:682–686.
   PubMedGoogle Scholar
• Saenger P. Turner's syndrome. N Engl J Med 1996;335: 1749–1754.
   PubMed Web of Science ®Google Scholar
• Speroff L, Glass R, Kase N. Assisted reproduction. In: Clinical gynecologic endocrinology and infertility. Speroff L, Glass R, Kase N, editors. Baltimore: Lippincott Williams and Wilkins; 1999. pp 365–366.
   Google Scholar
• Weiss L. Additional evidence of gradual loss of germ cells in the pathogenesis of streak ovaries in Turner's syndrome. J Med Genet 1971;8:540–544.
   PubMedGoogle Scholar
• Hovatta O. Pregnancies in women with Turner's syndrome. Ann Med 1999;31:106–110.
   PubMed Web of Science ®Google Scholar
• Singh RP, Carr DH. The anatomy and histology of XO human embryos and fetuses. Anat Rec 1966;155:369–383.
   PubMedGoogle Scholar
• Groll M, Cooper M. Menstrual function in Turner's syndrome. Obstet Gynecol 1976;47:225–226.
   PubMedGoogle Scholar
• Jones HW, Turner HH, Ferguson-Smith MA. Turner's syndrome and phenotype. Lancet 1966;1:1155.
   PubMedGoogle Scholar
• Pai GS, Leach DC, Weiss L, Wolf C, Van Dyke DL. Thyroid abnormalities in 20 children with Turner syndrome. J Pediatr 1977;91:267–269.
   PubMedGoogle Scholar
• Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol 1998;51:147–158.
   PubMed Web of Science ®Google Scholar
• Kwok C, Tyler-Smith C, Mendonca BB, Hughes I, Berkovitz GD, Goodfellow PN, Hawkins JR. Mutation analysis of the 2 kb 50 to SRY in XY females and XY intersex subjects. J Med Genet 1996;33:465–468.
   PubMedGoogle Scholar
• Dewhurst CJ, Ferreira HP, Gillett PG. Gonadal malignancy in XY females. J Obstet Gynaecol Br Commonw 1971;78:1077–1083.
   PubMedGoogle Scholar
• Verp MS, Simpson JL. Abnormal sexual differentiation and neoplasia. Cancer Genet Cytogenet 1987;25:191–218.
   PubMed Web of Science ®Google Scholar
• Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986;67:604–606.
   PubMed Web of Science ®Google Scholar
• Chen S, Sawicka J, Betterle C, Powell M, Prentice L, Volpato M, Prentice L, Volpato M, Rees Smith B, Furmaniak J. Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. J Clin Endocrinol Metab 1996;81:1871–1876.
   PubMed Web of Science ®Google Scholar
• Wheatcroft NJ, Toogood AA, Li TC, Cooke ID, Weetman AP. Detection of antibodies to ovarian antigens in women with premature ovarian failure. Clin Exp Immunol 1994;96:122–128.
   PubMedGoogle Scholar
• Conway GS, Kaltsas G, Patel A, Davies MC, Jacobs HS. Characterization of idiopathic premature ovarian failure. Fertil Steril 1996;65:337–341.
   PubMed Web of Science ®Google Scholar
• Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril 1990;53: 804–810.
   PubMed Web of Science ®Google Scholar
• Grasso E. Parotiti epodemiche pluricomplicate. G Mal Infett Parasit 1976;26:184–187.
   Google Scholar
• Familiari U, Larocca LM, Tamburrini E, Antinori A, Ortona L, Capelli A. Premenopausal cytomegalovirus oophoritis in a patient with AIDS. Aids 1991;5:458–459.
   PubMedGoogle Scholar
• Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PW, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329: 1141–1146.
   PubMed Web of Science ®Google Scholar
• Manolio TA, Furberg CD, Shemanski L, Psaty BM, O'Leary DH, Tracy RP, Bush TL. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group.. Circulation 1993;88(5 Pt 1):2163–2171.
   PubMedGoogle Scholar
• Shemesh J, Frenkel Y, Leibovitch L, Grossman E, Pines A, Motro M. Does hormone replacement therapy inhibit coronary artery calcification? Obstet Gynecol 1997;89:989–992.
   PubMed Web of Science ®Google Scholar
• Jonas HA, Kronmal RA, Psaty BM, Manolio TA, Meilahn EN, Tell GS, Tracy RP, Robbins JA, Anton-Culver H. Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis. CHS Collaborative Research Group. Cardiovascular Health Study. Ann Epidemiol 1996;6:314–323.
   PubMed Web of Science ®Google Scholar
• Guetta V, Quyyumi AA, Prasad A, Panza JA, Waclawiw M, Cannon RO III. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 1997;96:2795–2801.
   PubMed Web of Science ®Google Scholar
• Collins P, Rosano GM, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA. Cardiovascular protection by oestrogen – a calcium antagonist effect? Lancet 1993;341:1264–1265.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB. Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992;74:1396–1400.
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost 1993;70:584–587.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984;63:759–763.
   PubMed Web of Science ®Google Scholar
• Reginster JY, Sarlet N, Deroisy R, Albert A, Gaspard U, Franchimont P. Minimal levels of serum estradiol prevent postmenopausal bone loss. Calcif Tissue Int 1992;51: 340–343.
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991;325:756–762.
   PubMed Web of Science ®Google Scholar
• Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75–78.
   PubMed Web of Science ®Google Scholar
• Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996;87:6–12.
   PubMed Web of Science ®Google Scholar
• Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA 1997;277:543–547.
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;276:1389–1396.
   PubMed Web of Science ®Google Scholar
• Bakalov VK, Chen ML, Baron J, Hanton LB, Reynolds JC, Stratakis CA, Axelrod LE, Bondy CA. Bone mineral density and fractures in Turner syndrome. Am J Med 2003;115: 259–264.
   PubMed Web of Science ®Google Scholar
• Landin-Wilhelmsen K, Bryman I, Windh M, Wilhelmsen L. Osteoporosis and fractures in Turner syndrome-importance of growth promoting and oestrogen therapy. Clin Endocrinol (Oxf) 1999;51:497–502.
   PubMed Web of Science ®Google Scholar
• Davies MC, Gulekli B, Jacobs HS. Osteoporosis in Turner's syndrome and other forms of primary amenorrhoea. Clin Endocrinol (Oxf) 1995;43:741–746.
   PubMed Web of Science ®Google Scholar
• Neely EK, Marcus R, Rosenfeld RG, Bachrach LK. Turner syndrome adolescents receiving growth hormone are not osteopenic. J Clin Endocrinol Metab 1993;76:861–866.
   PubMedGoogle Scholar
• Mora S, Weber G, Guarneri MP, Nizzoli G, Pasolini D, Chiumello G. Effect of estrogen replacement therapy on bone mineral content in girls with Turner syndrome. Obstet Gynecol 1992;79:747–751.
   PubMed Web of Science ®Google Scholar
• Gravholt CH, Christian Klausen I, Weeke J, Sandahl CJ. Lp(a) and lipids in adult Turner's syndrome: impact of treatment with 17beta-estradiol and norethisterone. Atherosclerosis 2000;150:201–208.
   PubMedGoogle Scholar
• Landin-Wilhelmsen K, Bryman I, Wilhelmsen L. Cardiac malformations and hypertension, but not metabolic risk factors, are common in Turner syndrome. J Clin Endocrinol Metab 2001;86:4166–4170.
   PubMedGoogle Scholar
• Lanes R, Gunczler P, Palacios A, Villaroel O. Serum lipids, lipoprotein lp(a), and plasminogen activator inhibitor-1 in patients with Turner's syndrome before and during growth hormone and estrogen therapy. Fertil Steril 1997;68:473–477.
   PubMedGoogle Scholar
• Mizunuma H, Soda M, Okano H, Kagami I, Miyamoto S, Ohsawa M, et al. Changes in bone mineral density after orchidectomy and hormone replacement therapy in individuals with androgen insensitivity syndrome. Hum Reprod 1998;13:2816–2818.
   PubMedGoogle Scholar
• Munoz-Torres M, Jodar E, Quesada M, Escobar-Jimenez F. Bone mass in androgen-insensitivity syndrome: response to hormonal replacement therapy. Calcif Tissue Int 1995;57: 94–96.
   PubMedGoogle Scholar
• Mizunuma H, Soda M, Okano H, Kagami I, Miyamoto S, Ohsawa M, Ibuki Y. Changes in bone mineral density after orchidectomy and hormone replacement therapy in individuals with androgen insensitivity syndrome. Hum Reprod 1998;13:2816–2818.
   PubMedGoogle Scholar